Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

Daniel H Ryan,Geoffrey L Uy,Jorge E Cortes,Laura F Newell,Ellen K Ritchie,Robert K Stuart,Stephen A Strickland,Donna Hogge,Scott R Solomon,Richard M Stone,Dale L Bixby,Jonathan E Kolitz,Gary J Schiller,Matthew J Wieduwilt,Robert Ryan,Michael Chiarella,Arthur C Louie,Jeffrey E Lancet

doi:10.1182/blood-2018-99-111514

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

Daniel H Ryan, Geoffrey L Uy + Show 16 more

Open Access

https://doi.org/10.1182/blood-2018-99-111514

Copy DOI

Journal: Blood	Publication Date: Nov 29, 2018
Citations: 8

Affiliation: University of Rochester, University of Washington, The University of Texas MD Anderson Cancer Center, Oregon Health & Science University, Weill Cornell Medicine, Hollings Cancer Center, Vanderbilt University, Leukemia & Lymphoma Society of Canada, Northside Hospital, Dana-Farber Cancer Institute, University of Michigan–Ann Arbor, Northwell Health, University of California, Los Angeles, University of California, San Diego, Jazz Pharmaceuticals (United States), Moffitt Cancer Center

#Acute Myeloid Leukemia With Myelodysplasia-Related Changes #Research Funding + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.